Text size :

Rare diseases, Moroncini (Simi): “In EGPA targeted therapies to avoid cortisone”

ADNKRONOS

November 13, 2026

Rome, Nov 13. (Adnkronos Health) – In eosinophilic granulomatosis with polyangiitis, to achieve “true precision medicine, with targeted therapies, effective on all clinical manifestations and capable of avoiding the use of cortisone”, it is essential to “complete the knowledge of pathogenesis, to obtain reliable diagnostic and prognostic tests, anticipate disease recognition and establish prognosis, patient by patient”. This was stated by Gianluca Moroncini, vice-president and president-elect of the Italian Society of Internal Medicine (Simi) Emilia Romagna Marche section and scientific director of the regional congress, underway in Ancona today, November 13, and tomorrow.

“To anticipate the diagnosis of EGPA as much as possible – the expert continues – the population to be kept under particular attention is represented by subjects suffering from severe eosinophilic asthma, which in most cases constitutes the first clinical manifestation of the disease. Therefore, a virtuous collaboration between family doctors and specialists, such as allergists, pulmonologists, and internists with clinical immunology expertise, is essential.” This collaboration, Moroncini emphasizes, “can only be achieved through proper training of doctors already during their degree course and, subsequently, in postgraduate educational paths. The challenge, as with all rare diseases, is to create a medical class that is aware and capable of networking effectively.” Eosinophilic granulomatosis with polyangiitis is a rare and complex disease that can involve multiple organs and requires the integration of different competencies. “In our center – the expert specifies – the diagnostic-therapeutic pathway places the patient suffering from hypereosinophilia at the center, surrounded by a multispecialty medical team capable of jointly managing the person’s various clinical problems.” Interdisciplinary clinical expertise is supported by research. “Through ‘Marche Biobank’ and the Center for Precision Medicine for Rare Diseases – he points out – we can study, with informed consent, biological samples obtained from individual patients, with the aim of personalizing treatments and developing new knowledge on aspects of EGPA that are still little known.”

At the national level, the Simi working group dedicated to autoimmune and autoinflammatory diseases can contribute to the census of people with suspected or confirmed EGPA followed in Italian Internal Medicine departments, “which represent the backbone of the public health service”. The census, Moroncini concludes, “is the prerequisite for establishing a registry intended for the collection of clinical and epidemiological data useful for research and for improving the network for effective patient referral to reference centers capable of managing all aspects of the disease”.

Jiji Press

Related

Page TOP